Complete title: AALL1521 INCB 18424-269 A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children with De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
| Research Study Number | AALL1521 |
| Principal Investigator | Colleen Annesley, MD |
| Phase | II |
Other eligibility criteria may apply.
| Research Study Number | AALL1521 |
| Contact | Colleen Annesley, MD |
| Telephone | 206/987-2106 |
Keywords: Lymphoma, Burkitt; Hematologic Malignancies; Leukemia; Lymphoma; Lymphoproliferative Disorders; Pediatric Cancers, Miscellaneous; Lymphoma, Non-Hodgkin (NHL); Leukemia, Lymphoid; Immunoproliferative Disorders; Virus Diseases; Lymphoma, B-Cell; Leukemia, B-Cell, Lymphoblastic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Epstein-Barr Virus Infections; Herpesviridae Infections; Immune System Diseases; DNA Virus Infections; Tumor Virus Infections
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Please remember:
Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.